Table 2

Increases in Health Assessment Questionnaire Disability Index (HAQ-DI) per increase in total Sharp scores (TSS) and intermediate results

Trial	Treatment	HAQ change	SDAI change	f_ACT (HAQ/SDAI)	SDAI at end point	ACT-HAQ	HAQ at end point	DAM-HAQ	Total Sharp Score at end point	HAQ/TSS
Established RA
BELIRA	Glucocorticoids	0.23	11.3	0.0207	14.4	0.30	0.93	0.63	38.1	0.0165
ATTRACT	Infliximab+MTX	0.55	28.9	0.019	17.7	0.34	1.09	0.75	67.3	0.011
ATTRACT	Placebo	0.3	14.7	0.020	29.7	0.61	1.33	0.72	74.4	0.010
DE019	Adalimumab+MTX	0.53	22.1	0.024	18.6	0.45	0.92	0.47	67.5	0.007
LEF	Leflunomide	0.58	27.8	0.021	21.9	0.46	0.93	0.47	30.2	0.016
	MTX	0.62	30.3	0.020	20.4	0.42	0.88	0.46	26	0.018
	Salazopyrine	0.54	31.9	0.017	15.9	0.27	0.78	0.51	47	0.011
TEMPO	Etanercept+MTX	0.68	23.1	0.029	11.1	0.33	0.69	0.36	32.4	0.011
	Etanercept	0.55	22.3	0.025	13.8	0.34	0.83	0.49	26.5	0.018
	MTX	0.6	26	0.023	15.6	0.36	0.9	0.54	35.3	0.015
Mean	–	–	–	0.022±0.004	–	–	–	0.53±0.13	–	0.013±0.004
Early RA
ASPIRE	Infliximab+MTX	0.89	26.4	0.034	11.6	0.39	0.61	0.22	11.5	0.019
ASPIRE	MTX	0.73	22.5	0.032	15.5	0.50	0.81	0.31	15.4	0.020
ERA	Etanercept	0.76	27.1	0.028	17.6	0.49	0.7	0.21	11.6	0.018
ERA	MTX	0.75	25.4	0.030	18.4	0.54	0.68	0.14	13.3	0.010
PREMIER	Adalimumab	0.9	34.5	0.026	13.7	0.36	0.69	0.33	21.3	0.016
	MTX	0.88	35.7	0.025	13.7	0.34	0.62	0.28	27.4	0.010
	Adalimumab+MTX	1.06	39.7	0.027	8.7	0.23	0.41	0.18	20	0.009
Mean	–	–	–	0.029+0.003	–	–	–	0.24±0.07	–	0.015±0.005

ACT-HAQ, activity-related HAQ component; ASPIRE, ‘Active-controlled Study of Patents receiving Infliximab for the treatment of RA of Early onset’; ATTRACT, ‘Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy’; BELIRA, ‘BEst LIfe with Rheumatoid Arthritis’; DAM-HAQ, damage-related HAQ component; ERA, ‘Early Rheumatoid Arthritis’; f_ACT, change in HAQ seen per change in SDAI; LEF, leflunomide; MTX, methotrexate; SDAI, Simplified Disease Activity Index; TEMPO, ‘Trial of Etanercept and Methotrexate with radiographic Patient Outcomes’; TSS, total Sharp score.